Overview

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to enable optimal dose selection of LFF269 for potential future studies by providing additional information about the compounds safety, tolerability, pharmacokinetic and pharmacodynamic profiles.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals